Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Recruiting

• Conditions: Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma
• Interventions: Device: ClonoSEQ

• Registration Number: NCT05255354
• Lead Sponsor: Adaptive Biotechnologies

Brief Summary

In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-02-09
• Study First Submitted QC: 2022-02-23
• Study First Posted: 2022-02-24
• Study Start: 2022-06-01
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-21
• Last Update Posted: 2024-08-22
• Primary Completion: 2025-09-01
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Immunophenotypically confirmed diagnosis of follicular lymphoma (FL), Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to CAR infusion
• CAR-T product must meet manufacturer specifications
• PET measurable disease at the time a decision is made to prescribe CAR treatment
• Has sample from diagnosis or relapse available for genomic DNA extraction to identify patient's clonotype via clonoSEQ (see lab manual for details)

Read More

Exclusion Criteria

• Lack of archival diagnostic or fresh/archival relapse tissue for purposes of determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a clonotype identified by clonoSEQ, those patients will be removed from the study and excluded from analysis, but their samples will continued to be stored for future analysis as improvements to the analysis platform are made.
• No patients are to be excluded on the basis of gender, race, ethnic background, sexual orientation, or other demographic characteristics.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Diffuse Large B Cell Lymphoma	ClonoSEQ	For DLBCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, and potentially at relapse following CAR infusion. For DLBCL, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
Follicular Lymphoma	ClonoSEQ	For FL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For FL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
Mantle Cell Lymphoma	ClonoSEQ	For MCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For MCL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells

Primary Outcome Measures

Name	Time	Method
Primary Outcome: Predicting Progression Free Survival	0-18 months	Ability of ctDNA MRD assessment to predict progression-free survival (PFS) at 6 months following CAR infusion in DLBCL, FL and MCL patients.

Secondary Outcome Measures

Name	Time	Method
Secondary Objective: Correlation of minimal residual disease and tumor burden	0-18 months	-Determine the correlation between quantified MRD and metabolic tumor volume (MTV)
Secondary Objective continued: Looking at clinical information of minimal residual disease	0-18 months	-Determine the clinical utility of MRD assessments in an exploratory analysis
Secondary Objective continued: Additional correlations	0-18 months	-Determine the correlation between ctDNA-based and CTC-based MRD assessments in DLBCL/FL/MCL

Trial Locations

Locations (1)

Stanford Cancer Center; 🇺🇸 Palo Alto, California, United States